Stratus Medical has announced that it has been granted a patent for its Nimbus radiofrequency (RF) multitined expandable electrode from the US Patent and Trademark Office. According to a company press release, its new patent contains 29 method claims, including claims directed to nerve ablation for pain relief.
Bret Boudousquie, Stratus Medical CEO, Houston, USA, commented: “Nimbus RF ablation (RFA) is an important and rapidly growing treatment option for millions of patients suffering with chronic pain. We are delighted with the expansion of both our US and international patent portfolios to protect our technology in the marketplace.”
Boudousquie continued, “Nimbus is rapidly building market share due to its numerous clinical advantages over other large volume lesion RFA options, including faster procedure times, ease of use and lower procedure cost. We expect to see continued growth as interventional pain medicine physicians increase their utilisation of RFA with new procedure applications such as the knee, where coverage and payment was established in 2020 and improved significantly in 2021. Until recently, less than 1% of the millions of newly diagnosed knee arthritis patients have been treated with RFA. This presents an opportunity to help many chronic pain patients with the Nimbus technology.”
